Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06372145 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06372145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06372145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 16, 2024
Completion date
April 30, 2029
Enrollment
2,500 (estimated)
Sites
352

Conditions

As the registry lists them; a condition with its own page is linked.

progressive relapsing multiple sclerosis, relapsing multiple sclerosis, secondary progressive multiple sclerosis